We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where Evolent Health, Inc. (NYSE:EVH) stands against other stocks insiders were buying in Q1 2025.
About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while the blue-chip companies gained 0.9%. Meanwhile, the Nasdaq Composite dropped 0.5%. Some stocks were recovering from Friday losses after inflation data came in higher than expected, coupled with weak consumer sentiment, which heightened concerns about the U.S. economy’s stability, according to Investopedia.
As investors react to daily market changes, ongoing uncertainty continues to affect the market. During such times, insider trading often garners attention, as executive purchases of company stock can signal optimism about the company’s prospects. However, insider sales do not always indicate a lack of confidence—they may be influenced by personal financial reasons or a need for diversification. Executives often follow pre-arranged plans, like 10b5-1, to ensure transparency. While insider trading can offer valuable insights, it should be considered alongside a company’s financial health, market conditions, and industry shifts.
Our Methodology
What are some of the stocks insiders have been buying the most in the first quarter of the year? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least five insiders had purchased shares in January, February, and March. From there, we ranked the 20 stocks with the highest number of insiders purchasing shares.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
With each stock, we note the average price per share of these purchases and the stock’s market capitalization.
A doctor looking at their computer, discussing their patient’s care options with a group of experts.
Evolent Health, Inc. (NYSE:EVH)
Market Cap: $1.12 billion
Number of insiders buying: 9
The eighth stock among the 20 that insiders were buying the most in the first quarter of the year is Evolent Health, a provider of healthcare plans and benefits management services. Through its subsidiary Evolent Health LLC, it offers specialty care management services in oncology, cardiology, and musculoskeletal markets, focusing on improving patient outcomes and reducing costs. Its integrated platform supports health plan administration and value-based business infrastructure, offering services such as pharmacy benefits management, risk management, analytics, and leadership support. Additionally, Evolent provides Identifi, a proprietary technology system that aggregates data, manages care workflows, and engages patients, as well as Machinify Auth, a software platform utilizing artificial intelligence to optimize care processes. The company is based in Arlington, Virginia,
For the full year 2024, the company reported revenue of $2.55 billion, 30.1% up from $1.96 billion in 2023. The net loss for the year was $93.45 million, an improvement from the $142.26 million loss in 2023. Looking ahead to 2025, Evolent expects revenue between $2.06 billion and $2.11 billion, reflecting an annual growth rate of 15%-18%, excluding the impact of one-time contract changes in three Performance Suite contracts. The company also anticipates adjusted EBITDA in the range of $135 million to $165 million.
In March, nine insiders, including the company’s CEO, purchased a total of around $1.35 million worth of Evolent Health shares at an average price of $9.10 per share. Currently, the stock trades at $9.53 per share, having declined 15.29% year-to-date and 70.15% over the past 12 months.
Fourteen analysts rate Evolent Health stock as “Buy,” according to MarketBeat. The average price target of $17.71 suggests an upside of 85.88% from the latest price.
Evolent Health is also one of the 12 stocks that are about to explode.
Overall, EVH ranks 8th on our list of stocks insiders were buying in Q1 2025. While we acknowledge the potential of EVH our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center